Last reviewed · How we verify
NCT05345314
Endoscopic Grading of Intestinal Metaplasia
trial testing Narrow-band imaging endoscopy in Narrow-band Imaging in 242 participants. Completed in 24 April 2023.
28 February 2023
Quick facts
| Lead sponsor | Soonchunhyang University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 242 |
| Start date | 1 March 2022 |
| Primary completion | 28 February 2023 |
| Estimated completion | 24 April 2023 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Narrow-band imaging endoscopy
Conditions studied
- Narrow-band Imaging — all drugs for Narrow-band Imaging →
- Magnifying Endoscopy — all drugs for Magnifying Endoscopy →
- Gastric Intestinal Metaplasia — all drugs for Gastric Intestinal Metaplasia →
Sponsor
Soonchunhyang University Hospital
Who can join
Adults 20 to 80, any sex, with Narrow-band Imaging or Magnifying Endoscopy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Long-term Helicobacter pylori infection causes premalignant gastric conditions, such as atrophic gastritis and intestinal metaplasia. Image-enhanced endoscopy techniques such as narrow-band imaging (NBI) and magnifying endoscopy improve the diagnosis of gastric intestinal metaplasia (GIM). However, there are no comparative data on the utility of NBI and magnifying endoscopy for diagnosing GIM.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05345314
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Soonchunhyang University Hospital trials
Trials by the same sponsor.
- NCT07213596 — Virtual Reality Treatment for Trauma Related to COVID-19 Infection · NA · not yet recruiting
- NCT06950489 — Tegoprazan and Amoxicillin Dual Therapy · recruiting
- NCT06682533 — Tegoprazan- Versus PPI-based H. Pylori Eradication · recruiting
- NCT06684860 — RUT vs. Molecular Testing for H. Pylori · recruiting
- NCT06369896 — Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05345314 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Soonchunhyang University Hospital
- Last refreshed: 25 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05345314.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing